In this issue:
Outcomes in patients with primary refractory disease
OPTIMUM: Dara-CVRd extends PFS in ultra-high-risk disease
ROAR: Dabrafenib + trametinib for BRAF V600E-mutated cancer
OCTANS: Dara + VMP for transplant-ineligible disease
Teclistamab bests current therapies in triple-class exposed RRMM
Teclistamab vs physician’s choice for triple-class exposed RRMM
Incidence and management of CRS in MajesTEC-1
TGA registrations
Anti-CD38 mAb therapy linked to non-melanoma cutaneous tumours
Myeloma Clinical Education Workshop
Black patients more susceptible to bortezomib-induced peripheral neuropathy
Improved survival in elderly myeloma patients
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)